CA1284950C - Method for using diltiazem, verapamil or nifedipine for treating stroke - Google Patents

Method for using diltiazem, verapamil or nifedipine for treating stroke

Info

Publication number
CA1284950C
CA1284950C CA000522469A CA522469A CA1284950C CA 1284950 C CA1284950 C CA 1284950C CA 000522469 A CA000522469 A CA 000522469A CA 522469 A CA522469 A CA 522469A CA 1284950 C CA1284950 C CA 1284950C
Authority
CA
Canada
Prior art keywords
verapamil
diltiazem
nifedipine
stroke
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000522469A
Other languages
English (en)
French (fr)
Inventor
Frank W. Marcoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of CA1284950C publication Critical patent/CA1284950C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
CA000522469A 1986-01-10 1986-11-07 Method for using diltiazem, verapamil or nifedipine for treating stroke Expired - Fee Related CA1284950C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/818,505 US4654372A (en) 1986-01-10 1986-01-10 Method for using verapamil for treating stroke
US818,505 1986-01-10

Publications (1)

Publication Number Publication Date
CA1284950C true CA1284950C (en) 1991-06-18

Family

ID=25225695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000522469A Expired - Fee Related CA1284950C (en) 1986-01-10 1986-11-07 Method for using diltiazem, verapamil or nifedipine for treating stroke

Country Status (8)

Country Link
US (1) US4654372A (enExample)
EP (1) EP0229644B1 (enExample)
JP (1) JPS62167725A (enExample)
AT (1) ATE81006T1 (enExample)
CA (1) CA1284950C (enExample)
DE (1) DE3781904T2 (enExample)
ES (1) ES2046178T3 (enExample)
GR (1) GR3005998T3 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like
DE3737741A1 (de) * 1987-11-06 1989-05-18 Goedecke Ag Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
DK0429676T3 (enExample) * 1989-06-16 1997-03-10 Santen Pharmaceutical Co Ltd
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
KR20040078140A (ko) * 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
US20100041691A1 (en) * 2006-09-12 2010-02-18 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
WO2020157122A1 (en) * 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
WO2026002967A1 (en) 2024-06-24 2026-01-02 Universität Linz Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568677A (en) * 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents
JPS60130517A (ja) * 1983-12-16 1985-07-12 Mitsui Pharmaceut Inc アレルギ−性鼻炎治療剤

Also Published As

Publication number Publication date
DE3781904T2 (de) 1993-02-25
GR3005998T3 (enExample) 1993-06-07
ES2046178T3 (es) 1995-04-01
US4654372A (en) 1987-03-31
JPS62167725A (ja) 1987-07-24
EP0229644A3 (en) 1989-11-23
DE3781904D1 (de) 1992-11-05
EP0229644B1 (en) 1992-09-30
ATE81006T1 (de) 1992-10-15
EP0229644A2 (en) 1987-07-22

Similar Documents

Publication Publication Date Title
US5308862A (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
AU2002217111B2 (en) Methods of inducing ovulation using a non-polypeptide cAMP level modulator
US4444778A (en) Method and composition for treating atherosclerosis
WO1994021195A1 (en) Methods for protecting tissues and organs from ischemic damage
US4654372A (en) Method for using verapamil for treating stroke
Barker et al. Cardiovascular effects of anesthesia and operation
US4696924A (en) Method for using diltiazem for treating stroke
EP0526540B1 (en) Use of 5-ht4-receptor antagonists in the treatment of atrial fibrillation, including the prevention of stroke
US4696934A (en) Method for using nifedipine for treating stroke
EP0351755B1 (en) Combination of a calcium channel blocker and thromboxane a2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
CA2181225C (en) The use of sertraline to treat post myocardial infarction patients
US5162375A (en) Treatment of neuronal degeneration with 5HT1A agonists
EP0303357B1 (en) 4-Amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl)quinoline for (treatment of cardiac arrhythmias).
US6110927A (en) Loratadine for use as an antiarrhythmic
US5232950A (en) Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
CA1280694C (en) Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
Manani et al. Premedication with chlordemethyldiazepam and anxiolytic effect of diazepeam in implantology
ZA200104399B (en) Use of a 5ht2A and 5ht2A/C receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways.
JP2003512328A5 (enExample)
JP2003512328A (ja) レボシメンダンの新規用途
MXPA96002793A (en) Use of sertraline to treat patients after an infection of miocar
JPS6241208B2 (enExample)
EP0752859A1 (en) Pharmaceutical composition containing a class iii antiarrhythmic agent and a class iv antiarrhythmic agent
CN102204898A (zh) 用非多肽环一磷酸腺苷水平调节剂诱导排卵的方法
HUT52384A (en) Process for producing pharmaceutical compositions comprising dianhydrohexitol acyl derivatives

Legal Events

Date Code Title Description
MKLA Lapsed